8 Results for "

H3K18

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "H3K18" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-139108
CAS No.: 593273-05-3
Purity:  99.19%
Research Areas:  

Cancer

DCH36_06 is a potent and selective p300/CBP inhibitor with IC50s of 0.6 μM and 3.2 μM for p300 and CBP, respectively. DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity .
loading...
    loading...
Cat. No.: HY-N2126
CAS No.: 952068-57-4
Parishin E is a modulator of hexokinase 2, lactate dehydrogenase A, and silent information regulator 6 (sirtuin 6), and is also a component present in Gastrodia elata Blume . Parishin E reduces the expression of hexokinase 2 and lactate dehydrogenase A, thereby regulating the process of cellular glycolysis . Parishin E regulates the deacetylation mediated by silent information regulator 6 (Sirtuin 6), and inhibits histone 3 lactylation modifications at the H3K18la and H3K27la sites . Parishin E inhibits macrophage polarization . Parishin E alleviates LPS-induced inflammatory responses and suppresses the expression of pro-inflammatory cytokines . Parishin E exerts ameliorating effects on rheumatoid arthritis . Parishin E can be used in studies related to rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-184556
Research Areas:  

Cancer

dCBP-30 is an orally active, selective and dual-acting CBP/p300 PROTAC degrader with DC50 values of 0.05 nM (CBP) and 0.04 nM (p300), respectively. dCBP-30 reduces the acetylation levels of histone substrates H3K27, H3K18, H2BK5 and H2BK20, downregulates multiple myeloma-specific dependency programs, and induces multiple myeloma cell apoptosis. dCBP-30 triggers tumor regression and prolongs survival in multiple myeloma xenograft mouse models, and exhibits synergistic antiproliferative activity with dexamethasone. dCBP-30 can be used for the research of multiple myeloma .
loading...
    loading...
Cat. No.: HY-155229
CAS No.: 1065581-69-2
CBP/p300-IN-21 (Compound 5d) is a selective CBP/p300 inhibitor (IC50: 0.07 and 1.755 μM for p300 and CBP). CBP/p300-IN-21 decreases H3K18Ac level. CBP/p300-IN-21 inhibits growth of 4T1 tumor growth in mice .
loading...
    loading...
Cat. No.: HY-151812
CAS No.: 2999742-92-4
Purity:  98.03%
CBP/p300-IN-20 is a potent and selective p300/CBP inhibitor, with a pIC50 of 10.1 for p300. CBP/p300-IN-20 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-181669
CAS No.: 3034595-62-2
Research Areas:  

Cancer

P300-IN-6 is an orally active histone acetyltransferase p300 HAT domain inhibitor with human IC50 values of 7 nM. P300-IN-6 suppresses c-Myc expression, decreases H3K18ac and H3K27ac levels, and inhibits cancer cell proliferation.P300-IN-6 suppresses tumor growth in xenograft mouse models.P300-IN-6 can be used for the research of multiple myeloma .
loading...
    loading...
Cat. No.: HY-180889
CAS No.: 2257497-15-5
PROTAC BRD3 degrader-1 (compound D072) is a potent and selective PROTAC BRD3 degrader. PROTAC BRD3 degrader-1 selectively degrades BRD3 in mice, leading to the downregulation of H3K18ac without affecting BRD2 or BRD4. PROTAC BRD3 degrader-1 reduces intraocular inflammation in the experimental autoimmune uveitis (EAU) mouse mode and inhibits proinflammatory microglia in both uveitis retina and LPS (HY-D1056) treated mouse microglia cell line BV2. PROTAC BRD3 degrader-1 can be used for uveitis research .
loading...
    loading...
Cat. No.: HY-122081
CAS No.: 1904647-34-2
Research Areas:  

Cancer

CPI-644 is a selective EP300/CBP bromodomain inhibitor, with an IC50 of 0.18 µM against the CBP bromodomain. CPI-644 reduces the proportion of FOXP3 + cells and downregulates the expression of LAG-3, CTLA-4 and PD-1. CPI-644 can be used in cancer-related research .
loading...
    loading...